What best describes the concept of first-pass hepatic effect?

What best describes the concept of first-pass hepatic effect?

• A. The process by which drugs absorbed from the GI tract pass through the liver before entering systemic circulation.
• B. The bypass of hepatic metabolism by sublingual, buccal, nasal routes.
• C. The elimination of drug by kidney only.
• D. Hepatic metabolism occurs after intravenous infusion.

Answer: (A)

First-pass refers to what happens when a drug is absorbed from the gastrointestinal tract and is delivered to the liver via the portal vein before it reaches the rest of the body. In the liver, a portion of the drug is metabolized on its first encounter, which reduces the amount of unchanged drug that finalmente reaches systemic circulation—this is the liver’s first encounter with the drug shaping its bioavailability. The extent of this metabolism depends on hepatic enzymes and blood flow, so some drugs are heavily diminished after oral administration, while others remain largely intact. This is why many orally taken drugs have lower bioavailability and why alternate routes that bypass the portal circulation—such as sublingual, buccal, nasal, transdermal, or intravenous administration—can deliver more drug into systemic circulation. The concept does not describe eliminating hepatic metabolism after IV (which largely bypasses the first-pass effect) or purely renal elimination, and it is not about routes that merely avoid the liver.

First-pass refers to what happens when a drug is absorbed from the gastrointestinal tract and is delivered to the liver via the portal vein before it reaches the rest of the body. In the liver, a portion of the drug is metabolized on its first encounter, which reduces the amount of unchanged drug that finalmente reaches systemic circulation—this is the liver’s first encounter with the drug shaping its bioavailability. The extent of this metabolism depends on hepatic enzymes and blood flow, so some drugs are heavily diminished after oral administration, while others remain largely intact.

This is why many orally taken drugs have lower bioavailability and why alternate routes that bypass the portal circulation—such as sublingual, buccal, nasal, transdermal, or intravenous administration—can deliver more drug into systemic circulation. The concept does not describe eliminating hepatic metabolism after IV (which largely bypasses the first-pass effect) or purely renal elimination, and it is not about routes that merely avoid the liver.